This PPG has shown that certain clinical manifestafions of Marfan Syndrome (MFS), caused by mutations in fibrillin-1, are mediated by high levels of active TGF-B and that progression of selected phenotypes is blocked by the angiotensin type 1 (ATI) receptor antagonist losartan. Work from Project 2 (Rifkin) has shown that latent TGF-S is activated in cultures of MFS vascular smooth muscle cells (VSMCs), that the activator of latent TGF-B is an MMP, most likely MMP-9, and that TGF-B stimulates AT1 receptor expression. We propose a model in which defective matrix yields abnormal latent TGF-B sequestration followed by acfivafion, the active TGF-B sfimulates enhanced ATI receptor and MMP-9 expression, MMP-9 activates latent TGF-S, and ATI receptor signaling promotes confinued TGF-B expression. Thus, a cycle of activafion, enhanced expression, and activafion is established. However, the initiating event in this cycle is unknown, as are some ofthe interrelationships. This grant addresses three quesfions concerning TGF-B, ATI receptor, and MMPs in MFS.
In Aim 1, we will test whether perturbing the matrix results in the cycle of TGF-B formafion, ATI receptor expression up-regulation, and MMP-mediated latent TGF-B activation and if these changes are interrelated.
In Aim 2, we will use FACS to isolate and characterize cells of different lineages that contribute to aortic root VSMC populafions. Cells include cardiac nural crest, secondary heart field, mesoderm, and endothelium. Thus, we will determine whether or not abnormal cells in MFS arise from specific lineages, in which cells normally acfivate latent TGF-B, and have high levels of ATI receptor and MMPs. These results will be compared to those of Aim 1 in which cells generate these molecules because of failed matrix.
In Aim 3, we will generate MFS mice that are missing MMP-9 to establish if the in vitro activator MMP-9 is an in vivo acfivator. The completion of these aims will inform us as to the initiator of latent TGF-B activation, the cell that activates, and the nature ofthe in vivo activator.
of this work is that an understanding the fundamental cause of celllular phenotypes in Marfan Syndrome will allow us to develop novel therapeutic approaches. We, the PPG, demonstrated this possiblity in the last grant cycle. In this new proposal, we will attempt to identify addifional targets, as it is probable that different people or different fissues with MFS will require addifional therapies.
|Walji, Tezin A; Turecamo, Sarah E; DeMarsilis, Antea J et al. (2016) Characterization of metabolic health in mouse models of fibrillin-1 perturbation. Matrix Biol 55:63-76|
|Bellini, C; Korneva, A; Zilberberg, L et al. (2016) Differential ascending and descending aortic mechanics parallel aneurysmal propensity in a mouse model of Marfan syndrome. J Biomech 49:2383-9|
|Smaldone, Silvia; Ramirez, Francesco (2016) Fibrillin microfibrils in bone physiology. Matrix Biol 52-54:191-7|
|Horiguchi, Masahito; Todorovic, Vesna; Hadjiolova, Krassimira et al. (2015) Abrogation of both short and long forms of latent transforming growth factor-Î² binding protein-1 causes defective cardiovascular development and is perinatally lethal. Matrix Biol 43:61-70|
|Dabovic, Branka; Robertson, Ian B; Zilberberg, Lior et al. (2015) Function of latent TGFÎ² binding protein 4 and fibulin 5 in elastogenesis and lung development. J Cell Physiol 230:226-36|
|Cook, J R; Carta, L; Galatioto, J et al. (2015) Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes. Clin Genet 87:11-20|
|Cook, Jason R; Clayton, Nicholas P; Carta, Luca et al. (2015) Dimorphic effects of transforming growth factor-Î² signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler Thromb Vasc Biol 35:911-7|
|Sengle, Gerhard; Sakai, Lynn Y (2015) The fibrillin microfibril scaffold: A niche for growth factors and mechanosensation? Matrix Biol 47:3-12|
|Doyle, Jefferson J; Doyle, Alexander J; Wilson, Nicole K et al. (2015) A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife 4:|
|Robertson, Ian B; Horiguchi, Masahito; Zilberberg, Lior et al. (2015) Latent TGF-Î²-binding proteins. Matrix Biol 47:44-53|
Showing the most recent 10 out of 74 publications